日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin

CYP3A基因型与新型致癌转录抑制剂鲁比奈克汀的暴露量和清除率的变异性相关

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70173
Lubomirov, Rubin; Pérez-Ramos, Laura; Fudio, Salvador; Asín-Prieto, Eduardo; Ibarra-Gómez, Laura; Zubiaur, Pablo
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Description and Modeling of Relevant Demographic and Laboratory Variables in a Large Oncology Cohort to Generate Virtual Populations

对大型肿瘤队列中相关的统计学和实验室变量进行描述和建模，以生成虚拟人群

期刊:Pharmaceutics
影响因子:5.5
doi:10.3390/pharmaceutics16121548
Pérez-Ramos, Laura; Ibarra-Gómez, Laura; Lubomirov, Rubin; García-Cremades, María; Asín-Prieto, Eduardo; Fudio, Salvador; Zubiaur, Pablo
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study

鲁比奈德定与伊曲康唑联合用药在癌症患者中的药代动力学和安全性：一项药物相互作用研究

期刊:Marine Drugs
影响因子:5.4
doi:10.3390/md22040178
Moreno, Irene; Hernández, Tatiana; Calvo, Emiliano; Fudio, Salvador; Kahatt, Carmen; Martínez, Sara; Iglesias, Jorge Luis; Calafati, Román Octavio; Pérez-Ramos, Laura; Montilla, Lola; Zeaiter, Ali; Lubomirov, Rubin
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors

普洛卡布林联合吉西他滨治疗晚期实体瘤患者的I期安全性和有效性临床试验

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-024-01458-8
Ghalib, Mohammad H; Pulla, Mariano Provencio; De Miguel Luken, Maria J; de Juan, Virginia Calvo; Chaudhary, Imran; Hammami, M Bakri; Vikash, Sindhu; Maitra, Radhashree; Martinez, Sara; Kahatt, Carmen; Extremera, Sonia; Fudio, Salvador; Goel, Sanjay
发表日期：2024
文献求助 收藏

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

在关键的 ATLANTIS 研究中，基于模型的单药 lurbinectedin 头对头比较

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2023.1152371
Fudio, Salvador; Pérez-Ramos, Laura; Asín-Prieto, Eduardo; Zeaiter, Ali; Lubomirov, Rubin
发表日期：2023
文献求助 收藏

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

普利替地辛联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤患者的I期研究

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.5250
Mateos, María Victoria; Prosper, Felipe; Martin Sánchez, Jesús; Ocio, Enrique M; Oriol, Albert; Motlló, Cristina; Michot, Jean-Marie; Jarque, Isidro; Iglesias, Rebeca; Solé, María; Martínez, Sara; Kahatt, Carmen; Fudio, Salvador; Corral, Gema; Zeaiter, Ali; Montilla, Lola; Ribrag, Vincent
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏

Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS

利用超高效液相色谱-串联质谱法定量测定人血浆中鲁比奈克汀、其游离部分及其代谢物

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0283783
King, Nicholas; Garcia-Martinez, Soledad; Alcaraz, Eider; Grisalena, Alba; Lubomirov, Rubin; Altares, Raquel; Fernandez-Teruel, Carlos; Francesch, Andrés M; Avilés, Pablo M; Fudio, Salvador
代谢
发表日期：2023
文献求助 收藏

Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer

综合分析鲁比替定在小细胞肺癌中的疗效和安全性，以支持其剂量方案。

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-021-04366-3
Fernández-Teruel, Carlos; Fudio, Salvador; Lubomirov, Rubin
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis

鲁比替定对晚期实体瘤患者QTc间期的影响：一项暴露-反应分析

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-020-04153-6
Fudio, Salvador; Tabernero, Josep; Subbiah, Vivek; Chawla, Sant P; Moreno, Victor; Longo, Federico; Lopez, Rafael; Anton, Antonio; Trigo, Jose Manuel; Shapiro, Geoffrey; Jeong, Woondong; Villalobos, Victor Manuel; Lubomirov, Rubin; Fernandez-Teruel, Carlos; Alfaro, Vicente; Boni, Valentina
发表日期：2021
文献求助 收藏